Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.
Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.
复制标题
唾液酸修饰绿原酸脂质体与PD-1阻断剂联合免疫治疗有效增强抗肿瘤免疫反应和治疗效果
DOI：
10.1080/10717544.2021.1971797
复制
发表时间：
2021-12
期刊：
影响因子：
6
通讯作者：
Zhang T
中科院分区：
文献类型：
--
作者：
Li X;Zhu S;Yin P;Zhang S;Xu J;Zhang Q;Shi S;Zhang T
Melanoma is one of the most common malignant tumors. The anti-PD-1 antibody is used for the treatment of metastatic melanoma. Treatment success is only 35–40% and a range of immune-related adverse reactions can occur. Combination of anti-PD1 antibody therapy with other oncology therapies has been attempted. Herein, we assessed whether chlorogenic acid liposomes modified with sialic acid (CA-SAL) combined with anti-PD1 antibody treatment was efficacious as immunotherapy for melanoma. CA-SAL liposomes were prepared and characterized. In a mouse model of B16F10 tumor, mice were treated with an anti-PD1 antibody, CA-SAL, or combination of CA-SAL + anti-PD1 antibody, and compared with no treatment controls. The tumor inhibition rate, tumor-associated macrophages (TAMs) phenotype, T-cell activity, and safety were investigated. We observed a significant decrease in the proportion of M2-TAMs and CD4+Fop3+ T cells, while there was a significant increase in the proportion of M1-TAMs and CD8+ T cells, and in the activity of T cells, and thus in the tumor inhibition rate. No significant toxicity was observed in major organs. CA-SAL and anti-PD1 Ab combination therapy presented synergistic anti-tumor activity, which enhanced the efficacy of the PD-1 checkpoint blocker in a mouse model of melanoma. In summary, combination immunotherapy of CA-SAL and anti-PD1 Ab has broad prospects in improving the therapeutic effect of melanoma, and may provide a new strategy for clinical treatment.
登录
查看更多内容
基于可植入血凝块的免疫生态位，用于增强癌症疫苗接种
影响因子：
13.6
作者：
Fan Q;Ma Q;Bai J;Xu J;Fei Z;Dong Z;Maruyama A;Leong KW;Liu Z;Wang C
通讯作者：
Wang C
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
影响因子：
4.7
作者：
Marshall HT;Djamgoz MBA
通讯作者：
Djamgoz MBA
影响因子：
2.3
作者：
Hou, Ni;Liu, Na;Li, Jie
通讯作者：
Li, Jie
影响因子：
12.4
作者：
Huang, Shuai;Wang, Lu-Lu;Jiang, Jian-Dong
通讯作者：
Jiang, Jian-Dong